01652.HK
Fusen Pharmaceutical Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.74
−5.73%Year over year
Reported trailing growth
- Revenue
- -52.5%
- EBITDA
- -85.5%
- EBIT
- —
- EPS
- -66.7%
- Free cash flow
- +277.7%
- Operating cash flow
- +57.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -17.8%
- EBITDA
- -38.6%
- EBIT
- +97.5%
- Net income
- +93.8%
- EPS
- +93.9%
- Free cash flow
- -6.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026